HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Haleon’s EMEA Head Filippo Lanzi: There’s More To Innovation Than Rx-To-OTC Switch

Executive Summary

Health literacy and natural alternatives are two areas where Haleon's EMEA and LATAM head Filippo Lanzi sees potential for growth, in addition to Rx-to-OTC switch, he tells HBW Insight in an exclusive interview. Lanzi also digs deeper into Haleon's recently published first-half sales and earnings results and shares his thoughts on how the firm will meet the multiple challenges posed by the current social and economic environment. 

You may also be interested in...



Haleon Starts Standalone Life By Raising Sales Expectations

A better than expected first-half performance has put Haleon on a sure footing for the rest of the year following its recent demerger from GSK.

GSK's Haleon Sets Its Sights On Improving Health Inclusivity

As GSK prepares to launch its standalone consumer health business, Haleon, Tess Player, global head of expert and influencer marketing, talks to HBW Insight about the new company's plans to improve health inclusivity globally and empower 50 million consumers per year to self-care by 2025.

GSK Consumer Split Set For July, With Emerging Markets And Switch To Drive Growth

GSK will spin-off its consumer health business in July under the name Haleon. The standalone operation expects to outpace market growth rates by expanding in emerging markets, tapping into consumer demand for more natural products and delivering two Rx-to-OTC switches in the US.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel